J&J Medical Connect
SPRAVATO®

(esketamine)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

SPRAVATO® (esketamine)
Medical Information

Use in Patients with Comorbid Multiple Sclerosis

Last Updated: 02/11/2026

Summary

  • SPRAVATO is not indicated for the treatment of multiple sclerosis.
  • Clinical studies designed to evaluate the efficacy and/or safety of SPRAVATO in patients with multiple sclerosis have not been performed.
  • Comorbid multiple sclerosis was not an exclusion criterion in the SPRAVATO clinical trial programs.

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) conducted on 03 February 2026 did not identify any relevant citations pertaining to this topic.

Would you like to clear and leave your conversation? Message history will be lost.